BLTE News and Press, Belite Bio Inc From 04/25/23

Tinlarebant (aka LBS-008) continues to be safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at the 18-month time point A continued trend of slowing expansion of autofluorescence was observed The growth rate of incident atrophic retinal lesions was reduced compared t...

Virtual event on Wednesday, May 3 rd at 1:00 PM ET will feature key opinion leader Hendrik Scholl, M.D. from the University of Basel, Switzerland 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant in Stargardt disease 1 wi...

2023-04-03 20:39:04 ET Belite Bio, Inc (BLTE) Q4 2022 Earnings Conference Call April 3, 2023 4:30 PM ET Company Participants Tom Lin - Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call P...

2023-04-03 01:40:45 ET Belite Bio press release ( NASDAQ: BLTE ): FY Non-GAAP EPS of -$0.63. As of December 31, 2022, the Company had $42.1 million in cash. For further details see: Belite Bio Non-GAAP EPS of -$0.63

12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month efficacy and safety update expected during the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on April 25 42 ...

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical needs, will host a live webcast on Monday, April 3, 2023, at 4:30 p.m. Eastern time ...

Belite Bio (NASDAQ: BLTE) , TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding trea...

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD) There are currently no approved tr...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...

“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27 th at 11 AM ET SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based...